New combination therapy for recurrent ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new combination therapy (SYS6041 plus another drug) for women with recurrent ovarian cancer. It is for those whose cancer has come back after platinum chemotherapy, and who have not had too many previous treatments. The goal is to see if the combination can shrink tumors or slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with a confirmed diagnosis of high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
- Your cancer has come back after previous treatment (either platinum-sensitive or platinum-resistant), and you have had no more than 2 or 3 prior chemotherapy lines, depending on your type.
- If you have a BRCA mutation or HRD-positive tumor, you must have already tried a PARP inhibitor as maintenance therapy.
- You must have a tumor that can be measured on a scan, and you are able to do most daily activities (ECOG 0 or 1).
- You agree to use effective birth control during the study and for 8 months after the last dose.
- You cannot have taken a topoisomerase I inhibitor ADC drug before, or have certain other medical conditions like active infections, heart disease, or lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
This Phase 1 trial tests CPI-0209 combined with the standard platinum chemotherapy approach in people whose ovarian (or related) cancer has returned after prior platinum treatment. The goal is to find a safe dose and see whether this combination can help keep the cancer under control.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.